Australia
TGA Special Access and Authorised Prescriber pathways; unregistered medicine framework.
Review · Updated quarterly
Regulatory Intelligence
International regulatory landscape reviews.
Continually updated educational reviews comparing prescribing frameworks, product access, practitioner responsibilities and evolving evidence.
United States
Federal vs. state divergence; FDA-approved cannabinoids and state-level medical programs.
Review · Updated quarterly
Canada
Health Canada Cannabis Regulations and prescribing under the Access to Cannabis for Medical Purposes framework.
Review · Updated quarterly
United Kingdom
Unlicensed specials on the NHS and private specialist prescribing under Schedule 2.
Review · Updated quarterly
Germany
BfArM oversight, statutory insurance reimbursement and evolving pharmacy dispensing rules.
Review · Updated quarterly
Italy
Ministry of Health authorisation, regional access pathways and magistral preparations.
Review · Updated quarterly
Switzerland
Swissmedic regulation, recent legal reforms and physician-led access schemes.
Review · Updated quarterly
New Zealand
Medicinal Cannabis Scheme, minimum quality standards and prescribing responsibilities.
Review · Updated quarterly
South America
Comparative overview of frameworks across Argentina, Brazil, Colombia, Chile and Uruguay.
Review · Updated quarterly
Regulatory disclaimer. Regulations change frequently and vary by jurisdiction, scope of practice and product classification. These reviews are educational summaries and do not constitute legal advice. Practitioners remain responsible for understanding and complying with the laws applicable within their own jurisdiction.